Suppr超能文献

[两种缓释型氢化奎尼丁和奎尼丁制剂预防起搏诱发室性心动过速的疗效比较]

[Comparison of the efficacy of 2 delayed-action preparations of hydroquinidine and quinidine in the prevention of pacing induced ventricular tachycardia].

作者信息

Lévy S, Moyal C, Dolla E, Cointe R, Bru P, Lauribe P, Paganelli F, Chanu P, Gérard R

机构信息

Service de cardiologie, Hôpital Nord, Marseille.

出版信息

Arch Mal Coeur Vaiss. 1993 Sep;86(9):1359-63.

PMID:8129554
Abstract

The effects of two antiarrhythmic agents, hydroquinidine and quinidine on the prevention of pacing induced sustained ventricular tachycardia (VT) were studied in 14 patients. The underlying cardiac disease was old myocardial infarction (12 patients) or dilated cardiomyopathy (2 patients). Sustained monomorphic VT was induced in 14 patients during the initial electrophysiological study performed at least 48 hours after withdrawal of all antiarrhythmic therapy. The same stimulation protocol including 3 extrastimuli (S2 S3 S4) and 2 paced cycles (600 ms and 400 ms) was repeated at least 48 hours after the administration of 600 mg (2 gelules) per 24 hours of hydroquinidine or 1100 mg of quinidine arabogalactane sulphate, 3 to 4 hours after the last dose. This was an open, randomised, crossed over trial. Irrespective of the result observed with the first antiarrhythmic, used in an order attributed by a randomised table, the other antiarrhythmic was tested. Plasma concentrations were measured during the programmed stimulation test for both drugs. Induced VT was prevented by the two antiarrhythmics in 4 patients (28%). In one patient, VT was prevented by hydroquinidine but not by the quinidine compound, resulting in a prevention rate of 35% for the hydroquinidine. On the other hand, the quinidine compound was a total success in one patient in whom only a partial success was observed with hydroquinidine. VT remained inducible with both antiarrhythmics in 9 patients (64%).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

在14例患者中研究了两种抗心律失常药物——氢奎尼丁和奎尼丁对预防起搏诱发的持续性室性心动过速(VT)的效果。基础心脏疾病为陈旧性心肌梗死(12例患者)或扩张型心肌病(2例患者)。在停用所有抗心律失常治疗至少48小时后进行的初始电生理研究中,14例患者诱发了持续性单形性室性心动过速。在每24小时给予600毫克(2粒胶囊)氢奎尼丁或1100毫克阿拉伯半乳聚糖硫酸奎尼丁后至少48小时,且在最后一剂后3至4小时,重复相同的刺激方案,包括3个期外刺激(S2、S3、S4)和2个起搏周期(600毫秒和400毫秒)。这是一项开放、随机、交叉试验。不管使用随机表指定顺序的第一种抗心律失常药物观察到的结果如何,都要测试另一种抗心律失常药物。在程序刺激试验期间测量两种药物的血浆浓度。两种抗心律失常药物使4例患者(28%)的诱发室性心动过速得到预防。1例患者的室性心动过速被氢奎尼丁预防,但未被奎尼丁化合物预防,氢奎尼丁的预防率为35%。另一方面,奎尼丁化合物在1例患者中完全成功,而该患者使用氢奎尼丁仅部分成功。9例患者(64%)的室性心动过速在两种抗心律失常药物作用下仍可诱发。(摘要截短于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验